{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:55:42Z","timestamp":1760028942276},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,7,9]],"date-time":"2007-07-09T00:00:00Z","timestamp":1183939200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1007\/s11936-007-0021-6","type":"journal-article","created":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T02:58:49Z","timestamp":1184641129000},"page":"259-271","source":"Crossref","is-referenced-by-count":30,"title":["Adiposopathy: Treating pathogenic adipose tissue to reduce cardiovascular disease risk"],"prefix":"10.1007","volume":"9","author":[{"given":"Harold","family":"Bays","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena W.","family":"Rodbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan Bruce","family":"Schorr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Michael","family":"Gonz\u00e1lez-Campoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,7,9]]},"reference":[{"key":"21_CR1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/17460875.1.4.389","volume":"1","author":"H. Bays","year":"2006","unstructured":"Bays H, Ballantyne C: Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol 2006, 1:389\u2013420.","journal-title":"Future Lipidol"},{"key":"21_CR2","unstructured":"World Health Organization: Global Strategy on Diet, Physical Activity and Health. Available at http:\/\/www.who.int\/dietphysicalactivity\/publications\/facts\/obesity\/en\/ . Accessed November 19, 2005."},{"key":"21_CR3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1742-1241.2007.01336.x","volume":"61","author":"H. Bays","year":"2007","unstructured":"Bays H, Chapman R, Grandy S: The relationship of body mass index to diabetes mellitus, hypertension, and dyslipidemia: comparison of data of two national surveys. Int J Clin Pract 2007, 61:737\u2013747.","journal-title":"Int J Clin Pract"},{"key":"21_CR4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1517\/14796678.1.1.39","volume":"1","author":"H. Bays","year":"2005","unstructured":"Bays H, Abate N, Chandalia M: Adiposopathy: Sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiol 2005, 1:39\u201359.","journal-title":"Future Cardiol"},{"key":"21_CR5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1586\/14779072.3.3.393","volume":"3","author":"H. Bays","year":"2005","unstructured":"Bays H: Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Expert Rev Cardiovasc Ther 2005, 3:393\u2013404.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"21_CR6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1586\/14779072.4.6.871","volume":"4","author":"H. Bays","year":"2006","unstructured":"Bays H, Blonde L, Rosenson R: Adiposopathy: how do diet, exercise, weight loss and drug therapies improve metabolic disease? Expert Rev Cardiovasc Ther 2006, 4:871\u2013895.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"21_CR7","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/oby.2004.151","volume":"12","author":"H.E. Bays","year":"2004","unstructured":"Bays HE: Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004, 12:1197\u20131211.","journal-title":"Obes Res"},{"key":"21_CR8","first-page":"12","volume":"2","author":"H. Bays","year":"2006","unstructured":"Bays H: Adiposopathy: defining, diagnosing, and establishing indications to treat \u201csick fat\u201d: what are the regulatory considerations? US Endocrine Disease 2006, 2:12\u201314.","journal-title":"US Endocrine Disease"},{"key":"21_CR9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11883-006-0052-6","volume":"8","author":"H. Bays","year":"2006","unstructured":"Bays H, Dujovne CA: Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr Atheroscler Rep 2006, 8:144\u2013156.","journal-title":"Curr Atheroscler Rep"},{"key":"21_CR10","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1210\/jc.2004-0395","volume":"89","author":"E.E. Kershaw","year":"2004","unstructured":"Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548\u20132556.","journal-title":"J Clin Endocrinol Metab"},{"key":"21_CR11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1210\/er.2005-0022","volume":"27","author":"A. Schaffler","year":"2006","unstructured":"Schaffler A, Muller-Ladner U, Scholmerich J, Buchler C: Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev 2006, 27:449\u2013467.","journal-title":"Endocr Rev"},{"key":"21_CR12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/07315724.2003.10719316","volume":"22","author":"J.W. Anderson","year":"2003","unstructured":"Anderson JW, Kendall CW, Jenkins DJ: Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003, 22:331\u2013339.","journal-title":"J Am Coll Nutr"},{"key":"21_CR13","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2337\/diacare.14.9.802","volume":"14","author":"R.R. Henry","year":"1991","unstructured":"Henry RR, Gumbiner B: Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care 1991, 14:802\u2013823.","journal-title":"Diabetes Care"},{"key":"21_CR14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00125-004-1618-x","volume":"48","author":"N. Viguerie","year":"2005","unstructured":"Viguerie N, Vidal H, Arner P, et al.: Adipose tissue gene expression in obese subjects during low-fat and high-fat hypocaloric diets. Diabetologia 2005, 48:123\u2013131.","journal-title":"Diabetologia"},{"key":"21_CR15","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.2337\/dc06-0560","volume":"29","author":"R.F. Hamman","year":"2006","unstructured":"Hamman RF, Wing RR, Edelstein SL, et al.: Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006, 29:2102\u20132107.","journal-title":"Diabetes Care"},{"key":"21_CR16","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.amjcard.2006.06.048","volume":"98","author":"V.A. Diaz","year":"2006","unstructured":"Diaz VA, Player MS, Mainous AG 3rd, et al.: Competing impact of excess weight versus cardiorespiratory fitness on cardiovascular risk. Am J Cardiol 2006, 98:1468\u20131471.","journal-title":"Am J Cardiol"},{"key":"21_CR17","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2337\/dc05-2565","volume":"29","author":"D.E. Larson-Meyer","year":"2006","unstructured":"Larson-Meyer DE, Heilbronn LK, Redman LM, et al.: Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 2006, 29:1337\u20131344.","journal-title":"Diabetes Care"},{"key":"21_CR18","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/japplphysiol.00160.2005","volume":"99","author":"S.S. Bassuk","year":"2005","unstructured":"Bassuk SS, Manson JE: Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol 2005, 99:1193\u20131204.","journal-title":"J Appl Physiol"},{"key":"21_CR19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1467-789x.2000.00013.x","volume":"1","author":"A. Astrup","year":"2000","unstructured":"Astrup A, Finer N: Redefining type 2 diabetes: \u2018diabesity\u2019 or \u2018obesity dependent diabetes mellitus\u2019? Obes Rev 2000, 1:57\u201359.","journal-title":"Obes Rev"},{"key":"21_CR20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-277X.2004.00531.x","volume":"17","author":"A. Avenell","year":"2004","unstructured":"Avenell A, Brown TJ, McGee MA, et al.: What are the long-term benefits of weight reducing diets in adults? A system atic review of randomized controlled trials. J Hum Nutr Diet 2004, 17:317\u2013335.","journal-title":"J Hum Nutr Diet"},{"key":"21_CR21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/jama.293.1.96","volume":"293","author":"R.H. Eckel","year":"2005","unstructured":"Eckel RH: The dietary approach to obesity: is it the diet or the disorder? JAMA 2005, 293:96\u201397.","journal-title":"JAMA"},{"key":"21_CR22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00007256-200737010-00003","volume":"37","author":"D. Hansen","year":"2007","unstructured":"Hansen D, Dendale P, Berger J, et al.: The effects of exercise training on fat-mass loss in obese patients during energy intake restriction. Sports Med 2007, 37:31\u201346.","journal-title":"Sports Med"},{"key":"21_CR23","first-page":"580","volume":"35","author":"P. Clifton","year":"2006","unstructured":"Clifton P: The science behind weight loss diets\u2014a brief review. Aust Fam Physician 2006, 35:580\u2013582.","journal-title":"Aust Fam Physician"},{"key":"21_CR24","unstructured":"Rating the diets from Atkins(TM) to Dr. Sears Zone [no authors listed]. Consum Rep 2005, 70:18\u201322."},{"key":"21_CR25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.7326\/0003-4819-142-1-200501040-00012","volume":"142","author":"A.G. Tsai","year":"2005","unstructured":"Tsai AG, Wadden TA: Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann Intern Med 2005, 142:56\u201366.","journal-title":"Ann Intern Med"},{"key":"21_CR26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1210\/jc.2003-030723","volume":"89","author":"H. Bays","year":"2004","unstructured":"Bays H, Mandarino L, DeFronzo RA: Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004, 89:463\u2013478.","journal-title":"J Clin Endocrinol Metab"},{"key":"21_CR27","unstructured":"Loviscach M, Henry RR: Clinical significance of peroxisome proliferator-activated receptors in health and disease. Available at http:\/\/www.medscape.com\/viewarticle\/407915 . Accessed April 19, 2007."},{"key":"21_CR28","unstructured":"Meridia US Prescribing Information and Patient Information. Available at http:\/\/www.rxabbott.com\/pdf\/meridia.pdf Accessed February 20, 2007."},{"key":"21_CR29","first-page":"32","volume":"19","author":"H. Bays","year":"2007","unstructured":"Bays H: Adiposopathy: the endocannabinoid system as a therapeutic treatment target for dysfunctional \u201csick\u201d fat. California J Health System Pharmacy 2007, 19:32\u201339.","journal-title":"California J Health System Pharmacy"},{"key":"21_CR30","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/00004714-200210000-00014","volume":"22","author":"I. Anghelescu","year":"2002","unstructured":"Anghelescu I, Klawe C, Szegedi A: Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior. J Clin Psychopharmacol 2002, 22:521\u2013524.","journal-title":"J Clin Psychopharmacol"},{"key":"21_CR31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1620\/tjem.202.173","volume":"202","author":"N. Aydin","year":"2004","unstructured":"Aydin N, Topsever P, Kaya A, et al.: Orlist at, sibutramine, or combination therapy: which performs better on waist circum ference in relation with body mass index in obese patients? Tohoku J Exp Med 2004, 202:173\u2013180.","journal-title":"Tohoku J Exp Med"},{"key":"21_CR32","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.biopha.2004.09.006","volume":"58","author":"A. Kaya","year":"2004","unstructured":"Kaya A, Aydin N, Topsever P, et al.: Efficacy of sibutramine, orlist at and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 2004, 58:582\u2013587.","journal-title":"Biomed Pharmacother"},{"key":"21_CR33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/oby.2000.53","volume":"8","author":"T.A. Wadden","year":"2000","unstructured":"Wadden TA, Berkowitz RI, Womble LG, et al.: Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000, 8:431\u2013437.","journal-title":"Obes Res"},{"key":"21_CR34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1081\/ERC-200027356","volume":"30","author":"R. Sari","year":"2004","unstructured":"Sari R, Balci MK, Cakir M, et al.: Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res 2004, 30:159\u2013167.","journal-title":"Endocr Res"},{"key":"21_CR35","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/sj.ijo.0803498","volume":"31","author":"L.D. Whigham","year":"2007","unstructured":"Whigham LD, Dhurandhar NV, Rahko PS, Atkinson RL: Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status. Int J Obes (Lond) 2007, 31:850\u2013857.","journal-title":"Int J Obes (Lond)"},{"key":"21_CR36","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.283.13.1703","volume":"283","author":"J.M. Gardin","year":"2000","unstructured":"Gardin JM, Schumacher D, Constantine G, et al.: Valvular abnorm alities and cardiovascular status following exposure to dexfenfluramine or phentermine\/fenfluramine. JAMA 2000, 283:1703\u20131709.","journal-title":"JAMA"},{"key":"21_CR37","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1540-8175.2006.00278.x","volume":"23","author":"J.M. Gardin","year":"2006","unstructured":"Gardin JM, Constantine G, Davis K, et al.: Aortic valvular regurgitation: prevalence and clinical characteristics in a predominantly obese adult population not taking anorexigens. Echocardiography 2006, 23:569\u2013576.","journal-title":"Echocardiography"},{"key":"21_CR38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-200767010-00004","volume":"67","author":"J.C. Halford","year":"2007","unstructured":"Halford JC, Harrold JA, Boyland EJ, et al.: Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007, 67:27\u201355.","journal-title":"Drugs"},{"key":"21_CR39","unstructured":"Smith SR, Prosser W, Donahue D, et al.: Lorcaserin (APD356), a Selective 5-HT2C Agonist, Safely Induces Weight Loss in a 12-week Study of Healthy Obese Patients. Paper presented at the American Diabetes Association 66th Annual Scientific Sessions. Washington, DC; June 12, 2006."},{"key":"21_CR40","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2337\/diabetes.53.9.2250","volume":"53","author":"T. Masaki","year":"2004","unstructured":"Masaki T, Chiba S, Yasuda T, et al.: Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes 2004, 53:2250\u20132260.","journal-title":"Diabetes"},{"key":"21_CR41","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1172\/JCI15784","volume":"110","author":"K. Takahashi","year":"2002","unstructured":"Takahashi K, Suwa H, Ishikawa T, Kotani H: Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. J Clin Invest 2002, 110:1791\u20131799.","journal-title":"J Clin Invest"},{"key":"21_CR42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004850-200503000-00007","volume":"20","author":"M. Poyurovsky","year":"2005","unstructured":"Poyurovsky M, Pashinian A, Levi A, et al.: The effect of betahistine, a histamine H1 receptor agonist\/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol 2005, 20:101\u2013103.","journal-title":"Int Clin Psychopharmacol"},{"key":"21_CR43","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.ijo.0803446","volume":"31","author":"P. Kopelman","year":"2007","unstructured":"Kopelman P, Bryson A, Hickling R, et al.: Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 2007, 31:494\u2013499.","journal-title":"Int J Obes (Lond)"},{"key":"21_CR44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00126839-200607050-00002","volume":"7","author":"H. Bays","year":"2006","unstructured":"Bays H: The melanocortin system as a therapeutic treatment target for adiposity and adiposopathy. Drugs R D 2006, 7:289\u2013302.","journal-title":"Drugs R D"},{"key":"21_CR45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cmet.2006.08.002","volume":"4","author":"N. Erondu","year":"2006","unstructured":"Erondu N, Gantz I, Musser B, et al.: Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006, 4:275\u2013282.","journal-title":"Cell Metab"},{"key":"21_CR46","unstructured":"Genaer a Press Release: Genaera Corporation Announces Presentation of Data on Trodusquemine Mechanism of Action in Obesity. Available at http:\/\/www.genaera.com\/press_room.php?page=134 . Accessed January 16, 2007."},{"key":"21_CR47","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1043-2760(03)00079-1","volume":"14","author":"P. Pissios","year":"2003","unstructured":"Pissios P, Maratos-Flier E: Melanin-concentrating hormone: from fish skin to skinny mammals. Trends Endocrinol Metab 2003, 14:243\u2013248.","journal-title":"Trends Endocrinol Metab"},{"key":"21_CR48","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1021\/jm060572f","volume":"49","author":"F.X. Tavares","year":"2006","unstructured":"Tavares FX, Al-Barazanji KA, Bigham EC, et al.: Potent, selective, and orally efficacious antagonists of melanin-concentrating hormone receptor 1. J Med Chem 2006, 49:7095\u20137107.","journal-title":"J Med Chem"},{"key":"21_CR49","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0899-9007(98)00044-6","volume":"14","author":"A. Young","year":"1998","unstructured":"Young A, Denaro M: Roles of amylin in diabetes and in regulation of nutrient load. Nutrition 1998, 14:524\u2013527.","journal-title":"Nutrition"},{"key":"21_CR50","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s00125-005-1732-4","volume":"48","author":"I. Chapman","year":"2005","unstructured":"Chapman I, Parker B, Doran S, et al.: Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005, 48:838\u2013848.","journal-title":"Diabetologia"},{"key":"21_CR51","unstructured":"Gadde DM, Yonish GM, Foust MS, et al.: A 24-week randomized controlled trial of VI-0521, a combination weight loss therapy, in obese adults. Program and abstracts of the Annual Scientific Meeting of NAASO, The Obesity Society. Boston, MA; October 20\u201324, 2006. Abstract 55-OR."},{"key":"21_CR52","unstructured":"Greenway F, Anderson J Atkinson R et al.: Bupropion and zonisamide for the treatment of obesity. Program and abstracts of the Annual Scientific Meeting of NAASO, The Obesity Society. Boston, MA; October 20\u201324, 2006. Abstract 52-OR."},{"key":"21_CR53","unstructured":"Orexigen: Clinical Trials\u2014Data. Available at http:\/\/www.orexigen.com\/products\/clinical-trials\/ . Accessed February 4, 2007."},{"key":"21_CR54","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0014-4827(91)90261-R","volume":"196","author":"F. Gregoire","year":"1991","unstructured":"Gregoire F, Genart C, Hauser N, Remacle C: Glucocorticoids induce a drastic inhibition of proliferation and stimulate differentiation of adult rat fat cell precursors. Exp Cell Res 1991, 196:270\u2013278.","journal-title":"Exp Cell Res"},{"key":"21_CR55","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1210\/er.2003-0031","volume":"25","author":"J.W. Tomlinson","year":"2004","unstructured":"Tomlinson JW, Walker EA, Bujalska IJ, et al.: 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004, 25:831\u2013866.","journal-title":"Endocr Rev"},{"key":"21_CR56","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S0140-6736(96)11222-8","volume":"349","author":"I.J. Bujalska","year":"1997","unstructured":"Bujalska IJ, Kumar S, Stewart PM: Does central obesity reflect \u201cCushing\u2019s disease of the omentum\u201d? Lancet 1997, 349:1210\u20131213.","journal-title":"Lancet"},{"key":"21_CR57","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1172\/JCI107625","volume":"53","author":"L.B. Salans","year":"1974","unstructured":"Salans LB, Bray GA, Cushman SW, et al.: Glucose metabolism and the response to insulin by human adipose tissue in spontaneous and experimental obesity. Effects of dietary composition and adipose cell size. J Clin Invest 1974, 53:848\u2013856.","journal-title":"J Clin Invest"},{"key":"21_CR58","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/0026-0495(77)90061-0","volume":"26","author":"G.A. Bray","year":"1977","unstructured":"Bray GA, Glennon JA, Salans LB, et al.: Spontaneous and experimental human obesity: effects of diet and adipose cell size on lipolysis and lipogenesis. Metabolism 1977, 26:739\u2013747.","journal-title":"Metabolism"},{"key":"21_CR59","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1749-6632.2002.tb04292.x","volume":"967","author":"E. Ravussin","year":"2002","unstructured":"Ravussin E, Smith SR: Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci 2002, 967:363\u2013378.","journal-title":"Ann N Y Acad Sci"},{"key":"21_CR60","unstructured":"John-Soway J: Implications of Viewing Obesity as a Disease. Available at http:\/\/www.ama-assn.org\/ama\/pub\/category\/15630.html . Accessed February 28, 2007."}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-007-0021-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-007-0021-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-007-0021-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:56:31Z","timestamp":1559436991000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-007-0021-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,9]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["21"],"URL":"https:\/\/doi.org\/10.1007\/s11936-007-0021-6","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,9]]}}}